management of pediatric fibrous dysplasia/mccune-albright ......fibrous dysplasia/mccune-albright...
TRANSCRIPT
Management of Pediatric Fibrous Dysplasia/McCune-Albright
SyndromeAlison Boyce, MD
3rd Meeting of the FD/MAS International ConsortiumLeiden University Medical Center, Leiden, The
Netherlands
Fibrous Dysplasia/McCune-Albright syndrome:
A complex bone and endocrine disorder
Bone, pituitary, gonads, thyroid, adrenal, other
GH excess precociouspuberty
hyperthyroidismCushing’s syndrome
fibrous dysplasiarickets
Fibrous dysplasia
Café-au-lait
Precocious Pub.
Thyroid
Phosphate
Growth hormone
Cushing’s
0 5 10 15 20 30 50→
Age
Onset of manifestations of affected tissues
subclinical
clinically evident
spontaneous resolution possible
Most affected and unaffected tissues can be identified in childhood
Precocious Puberty in MAS
Ovary
Cyst
• Recurrent ovarian cysts
• Breast development, growth acceleration
• Vaginal bleeding when cysts resolve
ovarian cysts
Precocious Puberty in MAS
Treatment is needed to:
• Prevent disabling short stature in adulthood
• Prevent psychosocial consequences of early sexual maturation
AVOID SURGERY
Estrogen causes early closure of growth plates
Current Treatment Options
Tamoxifen (Eugster et al, 2003)• Alters estrogen receptor activity• 12 month prospective trial, 25 girls with MAS
Decreased: linear growth, bone age advancement and vaginal bleeding
increased: uterine volume
Letrozole (Feuillan et al, 2007)• Prevent estrogen production• 36 month pilot study, 9 girls with MAS
decrease: growth rate, bone age advancement and vaginal bleeding
one case of ovarian torsion
0 3 6 9 1 2
Y e a r s
Su
bje
cts
O n L e t r o z o l e P o s t L e t r o z o l e
S t a r t E n d
0
1
2
3
Bo
ne
Ag
e (
ye
ar
s)
/
Ch
ro
no
log
ic A
ge
(y
ea
rs
)
p < 0 . 0 0 0 1
Extended efficacy of letrozole in NIH cohort
n = 22mean Tx = 4.3y
length of treatment bone age advancement
Estrada et al, EJE 2016
Leydig cell hyperplasia
MAS Testicular Disease
Testicular lesions in ~85% Precocious puberty in ~15% Treatment: Spironolactone + letrozole
NO SURGERY!
Cancer has been rarely reported Ongoing monitoring
Leydig cell hyperplasia with Sertoli component
Collins JCEM 2003, Celi JCEM 2008
Thyroid Disease in MAS
goiter characteristic ultrasound
• US abnormalities in ~66%;
hyperthyroidism in ~30%
• T3 overproduction;
increased T3/T4 ratio (>20)
• Kids with US abnormalities
may develop
hyperthyroidism later
Collins JCEM 2003, Celi JCEM 2008
Thyroid Disease in MAS
Management
•Short-term: methimazole
• Long-term:
Surgery
prefer high-volume center
May regrow
Radioactive iodine
cancer reported
Growth Hormone Excess
• ~15% of patients
• Growth acceleration may be subtle, confounded by FD & endocrinopathies
GH & PP
PP
Lee, NEJM, 2002 (n=38) Prophylactic optic nerve decompression is not indicated
GH excess is a risk factors for vision lossCutler, Neurosurgery, 2006
Watchful waiting is superior to surgery (meta-analysis)Amit, PLos ONE 2011
FD patent obliteratedFD
GH excess: deformity and vision loss
optic canal
optic foramen blind
sphenoid bone
macrocephaly
Early GH excess treatment prevents morbidityBoyce…Collins, JCEM 2013 (n=129)
GH excess management issues: macrocephaly, vision & hearing loss
Treatment:•medication (octreotide, lanretotide, pegvisomant)• surgery (hypophosectomy, always difficult)•radiation (cancer risk)
macrocephalyOtic canal compression
•Presents age <1 year
•Early recognition is essential!
• Adrenalectomy if possible
• Caveat: spontaneous resolution in ~1/3
• Neurodevelopmental sequelae
Brown et al, JCEM, 2010
Cushing’s syndrome
Low Blood Phosphorus
renal phosphatewasting
FD + rickets Osteomalacia, Bone Pain
o
o
b
b
o = osteoid b = bone
Phosphate Wasting in FD
FD cells
FGF23 is made by FD cells
0
50
100
150
200
250
300
350
400
0 20 40 60 80
FG
F-2
3 (
RU
/m
l)
Skeletal Burden of FD
r=0.55, p<0.001
FGF23 is a Hormone that Causes Phosphate Wasting in FD
May show up during times of rapid growth (ex: infancy, puberty)May resolve in adulthood
More FD = More FGF23
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0,4
0,45
0,5
0-5 6-10 11-15 16-20 21-25 26-30 31-35 36-50
Fra
ctu
re r
ate
(#
fra
ctu
res
/pa
tie
nt/
ye
ar)
Age (years)(Leet ,JBMR, 2004)
hypophosphatema
normal phosphorus
Hypophosphatemia Increases Fractures
Hypophosphatemia: Treatment
1. Phosphorus Supplements
– Pills, powder, or liquid
– Short-acting, must give 3-5 times a day
– Diarrhea, GI discomfort
2. Calcitriol
– Prevents hyperparathyroidism (major side effect of Phosphorus supplements)
– May increase urine calcium
• Monitor urines and kidney ultrasounds
Questions?